BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19306899)

  • 1. Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro.
    Al-Abd AM; Lee SH; Kim SH; Cha JH; Park TG; Lee SJ; Kuh HJ
    J Control Release; 2009 Jul; 137(2):130-5. PubMed ID: 19306899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.
    Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
    J Control Release; 2006 Nov; 116(2):123-9. PubMed ID: 16831481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide.
    Lee SH; Kim SH; Park TG
    Biochem Biophys Res Commun; 2007 Jun; 357(2):511-6. PubMed ID: 17434451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI.
    Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
    Bioconjug Chem; 2008 Nov; 19(11):2156-62. PubMed ID: 18850733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
    Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
    J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
    Koldehoff M; Beelen DW; Elmaagacli AH
    J Leukoc Biol; 2008 Aug; 84(2):561-76. PubMed ID: 18458152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression.
    Huang HY; Kuo WT; Chou MJ; Huang YY
    J Biomed Mater Res A; 2011 Jun; 97(3):330-8. PubMed ID: 21465641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice.
    He XW; Yu X; Liu T; Yu SY; Chen DJ
    Chin Med J (Engl); 2008 Mar; 121(5):439-44. PubMed ID: 18364118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma.
    Kim WJ; Christensen LV; Jo S; Yockman JW; Jeong JH; Kim YH; Kim SW
    Mol Ther; 2006 Sep; 14(3):343-50. PubMed ID: 16765648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers.
    Zhu C; Jung S; Luo S; Meng F; Zhu X; Park TG; Zhong Z
    Biomaterials; 2010 Mar; 31(8):2408-16. PubMed ID: 19963269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
    Murata N; Takashima Y; Toyoshima K; Yamamoto M; Okada H
    J Control Release; 2008 Mar; 126(3):246-54. PubMed ID: 18215787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells.
    Ge YL; Zhang X; Zhang JY; Hou L; Tian RH
    Int Immunopharmacol; 2009 Apr; 9(4):389-95. PubMed ID: 19162240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes.
    Kim SH; Lee SH; Tian H; Chen X; Park TG
    J Drug Target; 2009 May; 17(4):311-7. PubMed ID: 19242850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
    Guo B; Zhang Y; Luo G; Li L; Zhang J
    Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
    Park K; Lee MY; Kim KS; Hahn SK
    Biomaterials; 2010 Jul; 31(19):5258-65. PubMed ID: 20378167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy.
    Kim WJ; Chang CW; Lee M; Kim SW
    J Control Release; 2007 Apr; 118(3):357-63. PubMed ID: 17313987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
    Alshamsan A; Hamdy S; Samuel J; El-Kadi AO; Lavasanifar A; Uludağ H
    Biomaterials; 2010 Feb; 31(6):1420-8. PubMed ID: 19913908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
    Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
    J Control Release; 2008 Jul; 129(2):107-16. PubMed ID: 18486981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
    Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ
    Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.
    Jiang G; Park K; Kim J; Kim KS; Hahn SK
    Mol Pharm; 2009; 6(3):727-37. PubMed ID: 19178144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.